首页 > 最新文献

Basic Research in Cardiology最新文献

英文 中文
Giant mitochondria in cardiomyocytes: cellular architecture in health and disease. 心肌细胞中的巨大线粒体:健康和疾病中的细胞结构。
IF 9.5 1区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2023-09-29 DOI: 10.1007/s00395-023-01011-3
Amy Li, Gerald J Shami, Lisa Griffiths, Sean Lal, Helen Irving, Filip Braet

Giant mitochondria are frequently observed in different disease models within the brain, kidney, and liver. In cardiac muscle, these enlarged organelles are present across diverse physiological and pathophysiological conditions including in ageing and exercise, and clinically in alcohol-induced heart disease and various cardiomyopathies. This mitochondrial aberration is widely considered an early structural hallmark of disease leading to adverse organ function. In this thematic paper, we discuss the current state-of-knowledge on the presence, structure and functional implications of giant mitochondria in heart muscle. Despite its demonstrated reoccurrence in different heart diseases, the literature on this pathophysiological phenomenon remains relatively sparse since its initial observations in the early 60s. We review historical and contemporary investigations from cultured cardiomyocytes to human tissue samples to address the role of giant mitochondria in cardiac health and disease. Finally, we discuss their significance for the future development of novel mitochondria-targeted therapies to improve cardiac metabolism and functionality.

在大脑、肾脏和肝脏的不同疾病模型中经常观察到巨大的线粒体。在心肌中,这些增大的细胞器存在于各种生理和病理生理条件下,包括衰老和运动,以及临床上酒精诱导的心脏病和各种心肌病。这种线粒体畸变被广泛认为是导致器官功能不良的疾病的早期结构标志。在这篇主题论文中,我们讨论了心肌中巨大线粒体的存在、结构和功能意义的知识现状。尽管它在不同的心脏病中反复出现,但自60年代初首次观察以来,关于这种病理生理现象的文献仍然相对稀少。我们回顾了从培养的心肌细胞到人体组织样本的历史和当代研究,以探讨巨型线粒体在心脏健康和疾病中的作用。最后,我们讨论了它们对未来开发新型线粒体靶向疗法以改善心脏代谢和功能的意义。
{"title":"Giant mitochondria in cardiomyocytes: cellular architecture in health and disease.","authors":"Amy Li, Gerald J Shami, Lisa Griffiths, Sean Lal, Helen Irving, Filip Braet","doi":"10.1007/s00395-023-01011-3","DOIUrl":"10.1007/s00395-023-01011-3","url":null,"abstract":"<p><p>Giant mitochondria are frequently observed in different disease models within the brain, kidney, and liver. In cardiac muscle, these enlarged organelles are present across diverse physiological and pathophysiological conditions including in ageing and exercise, and clinically in alcohol-induced heart disease and various cardiomyopathies. This mitochondrial aberration is widely considered an early structural hallmark of disease leading to adverse organ function. In this thematic paper, we discuss the current state-of-knowledge on the presence, structure and functional implications of giant mitochondria in heart muscle. Despite its demonstrated reoccurrence in different heart diseases, the literature on this pathophysiological phenomenon remains relatively sparse since its initial observations in the early 60s. We review historical and contemporary investigations from cultured cardiomyocytes to human tissue samples to address the role of giant mitochondria in cardiac health and disease. Finally, we discuss their significance for the future development of novel mitochondria-targeted therapies to improve cardiac metabolism and functionality.</p>","PeriodicalId":8723,"journal":{"name":"Basic Research in Cardiology","volume":"118 1","pages":"39"},"PeriodicalIF":9.5,"publicationDate":"2023-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10541842/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41093037","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The roles of intracellular proteolysis in cardiac ischemia-reperfusion injury. 细胞内蛋白水解在心脏缺血再灌注损伤中的作用。
IF 9.5 1区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2023-09-28 DOI: 10.1007/s00395-023-01007-z
Bridgette Hartley, Wesam Bassiouni, Richard Schulz, Olivier Julien

Ischemic heart disease remains a leading cause of human mortality worldwide. One form of ischemic heart disease is ischemia-reperfusion injury caused by the reintroduction of blood supply to ischemic cardiac muscle. The short and long-term damage that occurs due to ischemia-reperfusion injury is partly due to the proteolysis of diverse protein substrates inside and outside of cardiomyocytes. Ischemia-reperfusion activates several diverse intracellular proteases, including, but not limited to, matrix metalloproteinases, calpains, cathepsins, and caspases. This review will focus on the biological roles, intracellular localization, proteolytic targets, and inhibitors of these proteases in cardiomyocytes following ischemia-reperfusion injury. Recognition of the intracellular function of each of these proteases includes defining their activation, proteolytic targets, and their inhibitors during myocardial ischemia-reperfusion injury. This review is a step toward a better understanding of protease activation and involvement in ischemic heart disease and developing new therapeutic strategies for its treatment.

缺血性心脏病仍然是全世界人类死亡的主要原因。缺血性心脏病的一种形式是由缺血心肌重新引入血液供应引起的缺血再灌注损伤。缺血再灌注损伤引起的短期和长期损伤部分是由于心肌细胞内外不同蛋白质底物的蛋白水解。缺血再灌注激活几种不同的细胞内蛋白酶,包括但不限于基质金属蛋白酶、钙蛋白酶、组织蛋白酶和半胱天冬酶。这篇综述将集中于心肌缺血再灌注损伤后这些蛋白酶的生物学作用、细胞内定位、蛋白水解靶点和抑制剂。对这些蛋白酶中每一种的细胞内功能的识别包括确定它们在心肌缺血再灌注损伤过程中的激活、蛋白水解靶点及其抑制剂。这篇综述是朝着更好地了解蛋白酶激活和参与缺血性心脏病以及开发新的治疗策略迈出的一步。
{"title":"The roles of intracellular proteolysis in cardiac ischemia-reperfusion injury.","authors":"Bridgette Hartley, Wesam Bassiouni, Richard Schulz, Olivier Julien","doi":"10.1007/s00395-023-01007-z","DOIUrl":"10.1007/s00395-023-01007-z","url":null,"abstract":"<p><p>Ischemic heart disease remains a leading cause of human mortality worldwide. One form of ischemic heart disease is ischemia-reperfusion injury caused by the reintroduction of blood supply to ischemic cardiac muscle. The short and long-term damage that occurs due to ischemia-reperfusion injury is partly due to the proteolysis of diverse protein substrates inside and outside of cardiomyocytes. Ischemia-reperfusion activates several diverse intracellular proteases, including, but not limited to, matrix metalloproteinases, calpains, cathepsins, and caspases. This review will focus on the biological roles, intracellular localization, proteolytic targets, and inhibitors of these proteases in cardiomyocytes following ischemia-reperfusion injury. Recognition of the intracellular function of each of these proteases includes defining their activation, proteolytic targets, and their inhibitors during myocardial ischemia-reperfusion injury. This review is a step toward a better understanding of protease activation and involvement in ischemic heart disease and developing new therapeutic strategies for its treatment.</p>","PeriodicalId":8723,"journal":{"name":"Basic Research in Cardiology","volume":"118 1","pages":"38"},"PeriodicalIF":9.5,"publicationDate":"2023-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41103931","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Ketone body 3-hydroxybutyrate elevates cardiac output through peripheral vasorelaxation and enhanced cardiac contractility. 酮体3-羟基丁酸通过外周血管舒张和增强心脏收缩力来提高心输出量。
IF 9.5 1区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2023-09-09 DOI: 10.1007/s00395-023-01008-y
Casper Homilius, Jacob Marthinsen Seefeldt, Julie Sørensen Axelsen, Tina Myhre Pedersen, Trine Monberg Sørensen, Roni Nielsen, Henrik Wiggers, Jakob Hansen, Vladimir V Matchkov, Hans Erik Bøtker, Ebbe Boedtkjer

The ketone body 3-hydroxybutyrate (3-OHB) increases cardiac output and myocardial perfusion without affecting blood pressure in humans, but the cardiovascular sites of action remain obscure. Here, we test the hypothesis in rats that 3-OHB acts directly on the heart to increase cardiac contractility and directly on blood vessels to lower systemic vascular resistance. We investigate effects of 3-OHB on (a) in vivo hemodynamics using echocardiography and invasive blood pressure measurements, (b) isolated perfused hearts in Langendorff systems, and (c) isolated arteries and veins in isometric myographs. We compare Na-3-OHB to equimolar NaCl added to physiological buffers or injection solutions. At plasma concentrations of 2-4 mM in vivo, 3-OHB increases cardiac output (by 28.3±7.8%), stroke volume (by 22.4±6.0%), left ventricular ejection fraction (by 13.3±4.6%), and arterial dP/dtmax (by 31.9±11.2%) and lowers systemic vascular resistance (by 30.6±11.2%) without substantially affecting heart rate or blood pressure. Applied to isolated perfused hearts at 3-10 mM, 3-OHB increases left ventricular developed pressure by up to 26.3±7.4 mmHg and coronary perfusion by up to 20.2±9.5%. Beginning at 1-3 mM, 3-OHB relaxes isolated coronary (EC50=12.4 mM), cerebral, femoral, mesenteric, and renal arteries as well as brachial, femoral, and mesenteric veins by up to 60% of pre-contraction within the pathophysiological concentration range. Of the two enantiomers that constitute racemic 3-OHB, D-3-OHB dominates endogenously; but tested separately, the enantiomers induce similar vasorelaxation. We conclude that increased cardiac contractility and generalized systemic vasorelaxation can explain the elevated cardiac output during 3-OHB administration. These actions strengthen the therapeutic rationale for 3-OHB in heart failure management.

酮体3-羟基丁酸酯(3-OHB)在不影响人体血压的情况下增加心输出量和心肌灌注,但其心血管作用部位仍不清楚。在这里,我们在大鼠中检验了3-OHB直接作用于心脏以增加心脏收缩力和直接作用于血管以降低全身血管阻力的假设。我们研究了3-OHB对(a)使用超声心动图和有创血压测量的体内血液动力学的影响,(b)Langendorff系统中的离体灌注心脏,以及(c)等长肌图中的分离动脉和静脉的影响。我们将Na-3-OHB与添加到生理缓冲液或注射溶液中的等摩尔NaCl进行比较。在体内2-4 mM的血浆浓度下,3-OHB可增加心输出量(28.3±7.8%)、射血容量(22.4±6.0%)、左心室射血分数(13.3±4.6%)和动脉dP/dtmax(31.9±11.2%),并降低全身血管阻力(30.6±11.2%。3-OHB应用于3-10 mM的离体灌注心脏,可使左心室发展压力增加26.3±7.4 mmHg,使冠状动脉灌注增加20.2±9.5%。从1-3 mM开始,3-OHB可放松离体冠状动脉(EC50=12.4 mM)、脑动脉、股动脉、肠系膜动脉和肾动脉,和肠系膜静脉在病理生理浓度范围内收缩前高达60%。在构成外消旋3-OHB的两种对映体中,D-3-OHB内源性占主导地位;但单独测试,对映体诱导类似的血管舒张。我们的结论是,心脏收缩力的增加和全身血管舒张可以解释3-OHB给药期间心输出量的升高。这些作用加强了3-OHB在心力衰竭管理中的治疗原理。
{"title":"Ketone body 3-hydroxybutyrate elevates cardiac output through peripheral vasorelaxation and enhanced cardiac contractility.","authors":"Casper Homilius, Jacob Marthinsen Seefeldt, Julie Sørensen Axelsen, Tina Myhre Pedersen, Trine Monberg Sørensen, Roni Nielsen, Henrik Wiggers, Jakob Hansen, Vladimir V Matchkov, Hans Erik Bøtker, Ebbe Boedtkjer","doi":"10.1007/s00395-023-01008-y","DOIUrl":"10.1007/s00395-023-01008-y","url":null,"abstract":"<p><p>The ketone body 3-hydroxybutyrate (3-OHB) increases cardiac output and myocardial perfusion without affecting blood pressure in humans, but the cardiovascular sites of action remain obscure. Here, we test the hypothesis in rats that 3-OHB acts directly on the heart to increase cardiac contractility and directly on blood vessels to lower systemic vascular resistance. We investigate effects of 3-OHB on (a) in vivo hemodynamics using echocardiography and invasive blood pressure measurements, (b) isolated perfused hearts in Langendorff systems, and (c) isolated arteries and veins in isometric myographs. We compare Na-3-OHB to equimolar NaCl added to physiological buffers or injection solutions. At plasma concentrations of 2-4 mM in vivo, 3-OHB increases cardiac output (by 28.3±7.8%), stroke volume (by 22.4±6.0%), left ventricular ejection fraction (by 13.3±4.6%), and arterial dP/dt<sub>max</sub> (by 31.9±11.2%) and lowers systemic vascular resistance (by 30.6±11.2%) without substantially affecting heart rate or blood pressure. Applied to isolated perfused hearts at 3-10 mM, 3-OHB increases left ventricular developed pressure by up to 26.3±7.4 mmHg and coronary perfusion by up to 20.2±9.5%. Beginning at 1-3 mM, 3-OHB relaxes isolated coronary (EC<sub>50</sub>=12.4 mM), cerebral, femoral, mesenteric, and renal arteries as well as brachial, femoral, and mesenteric veins by up to 60% of pre-contraction within the pathophysiological concentration range. Of the two enantiomers that constitute racemic 3-OHB, D-3-OHB dominates endogenously; but tested separately, the enantiomers induce similar vasorelaxation. We conclude that increased cardiac contractility and generalized systemic vasorelaxation can explain the elevated cardiac output during 3-OHB administration. These actions strengthen the therapeutic rationale for 3-OHB in heart failure management.</p>","PeriodicalId":8723,"journal":{"name":"Basic Research in Cardiology","volume":"118 1","pages":"37"},"PeriodicalIF":9.5,"publicationDate":"2023-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10492777/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10209192","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cardiac fibroblast GSK-3α aggravates ischemic cardiac injury by promoting fibrosis, inflammation, and impairing angiogenesis. 心脏成纤维细胞GSK-3α通过促进纤维化、炎症和损害血管生成加重缺血性心脏损伤。
IF 7.5 1区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2023-09-01 DOI: 10.1007/s00395-023-01005-1
Prachi Umbarkar, Suma Ejantkar, Sulivette Y Ruiz Ramirez, Angelica Toro Cora, Qinkun Zhang, Sultan Tousif, Hind Lal

Myocardial infarction (MI) is the leading cause of death worldwide. Glycogen synthase kinase-3 (GSK-3) has been considered to be a promising therapeutic target for cardiovascular diseases. GSK-3 is a family of ubiquitously expressed serine/threonine kinases. GSK-3 isoforms appear to play overlapping, unique, and even opposing functions in the heart. Previously, our group identified that cardiac fibroblast (FB) GSK-3β acts as a negative regulator of fibrotic remodeling in the ischemic heart. However, the role of FB-GSK-3α in MI pathology is not defined. To determine the role of FB-GSK-3α in MI-induced adverse cardiac remodeling, GSK-3α was deleted specifically in the residential fibroblast or myofibroblast (MyoFB) using tamoxifen (TAM) inducible Tcf21 or Periostin (Postn) promoter-driven Cre recombinase, respectively. Echocardiographic analysis revealed that FB- or MyoFB-specific GSK-3α deletion prevented the development of dilative remodeling and cardiac dysfunction. Morphometrics and histology studies confirmed improvement in capillary density and a remarkable reduction in hypertrophy and fibrosis in the KO group. We harvested the hearts at 4 weeks post-MI and analyzed signature genes of adverse remodeling. Specifically, qPCR analysis was performed to examine the gene panels of inflammation (TNFα, IL-6, IL-1β), fibrosis (COL1A1, COL3A1, COMP, Fibronectin-1, Latent TGF-β binding protein 2), and hypertrophy (ANP, BNP, MYH7). These molecular markers were essentially normalized due to FB-specific GSK-3α deletion. Further molecular studies confirmed that FB-GSK-3α could regulate NF-kB activation and expression of angiogenesis-related proteins. Our findings suggest that FB-GSK-3α plays a critical role in the pathological cardiac remodeling of ischemic hearts, therefore, it could be therapeutically targeted.

心肌梗死(MI)是世界范围内导致死亡的主要原因。糖原合成酶激酶-3 (GSK-3)被认为是一种有前景的治疗心血管疾病的靶点。GSK-3是一个普遍表达的丝氨酸/苏氨酸激酶家族。GSK-3亚型似乎在心脏中发挥重叠、独特甚至相反的功能。之前,我们的研究小组发现,心脏成纤维细胞(FB) GSK-3β在缺血心脏中作为纤维化重塑的负调节因子。然而,FB-GSK-3α在心肌梗死病理中的作用尚未明确。为了确定FB-GSK-3α在mi诱导的不良心脏重构中的作用,分别使用他莫昔芬(TAM)诱导的Tcf21或Periostin (Postn)启动子驱动的Cre重组酶,在居住成纤维细胞或肌成纤维细胞(MyoFB)中特异性地删除GSK-3α。超声心动图分析显示FB-或myofb特异性GSK-3α缺失可阻止扩张性重构和心功能障碍的发生。形态计量学和组织学研究证实,KO组毛细血管密度改善,肥厚和纤维化显著减少。我们在心肌梗死后4周采集心脏,分析不良重构的特征基因。具体而言,采用qPCR分析检测炎症(TNFα、IL-6、IL-1β)、纤维化(COL1A1、COL3A1、COMP、Fibronectin-1、Latent TGF-β结合蛋白2)和肥大(ANP、BNP、MYH7)基因组。由于fb特异性GSK-3α缺失,这些分子标记基本上归一化。进一步的分子研究证实FB-GSK-3α可以调节NF-kB的激活和血管生成相关蛋白的表达。我们的研究结果表明FB-GSK-3α在缺血性心脏的病理性心脏重塑中起关键作用,因此可以作为治疗靶点。
{"title":"Cardiac fibroblast GSK-3α aggravates ischemic cardiac injury by promoting fibrosis, inflammation, and impairing angiogenesis.","authors":"Prachi Umbarkar, Suma Ejantkar, Sulivette Y Ruiz Ramirez, Angelica Toro Cora, Qinkun Zhang, Sultan Tousif, Hind Lal","doi":"10.1007/s00395-023-01005-1","DOIUrl":"10.1007/s00395-023-01005-1","url":null,"abstract":"<p><p>Myocardial infarction (MI) is the leading cause of death worldwide. Glycogen synthase kinase-3 (GSK-3) has been considered to be a promising therapeutic target for cardiovascular diseases. GSK-3 is a family of ubiquitously expressed serine/threonine kinases. GSK-3 isoforms appear to play overlapping, unique, and even opposing functions in the heart. Previously, our group identified that cardiac fibroblast (FB) GSK-3β acts as a negative regulator of fibrotic remodeling in the ischemic heart. However, the role of FB-GSK-3α in MI pathology is not defined. To determine the role of FB-GSK-3α in MI-induced adverse cardiac remodeling, GSK-3α was deleted specifically in the residential fibroblast or myofibroblast (MyoFB) using tamoxifen (TAM) inducible Tcf21 or Periostin (Postn) promoter-driven Cre recombinase, respectively. Echocardiographic analysis revealed that FB- or MyoFB-specific GSK-3α deletion prevented the development of dilative remodeling and cardiac dysfunction. Morphometrics and histology studies confirmed improvement in capillary density and a remarkable reduction in hypertrophy and fibrosis in the KO group. We harvested the hearts at 4 weeks post-MI and analyzed signature genes of adverse remodeling. Specifically, qPCR analysis was performed to examine the gene panels of inflammation (TNFα, IL-6, IL-1β), fibrosis (COL1A1, COL3A1, COMP, Fibronectin-1, Latent TGF-β binding protein 2), and hypertrophy (ANP, BNP, MYH7). These molecular markers were essentially normalized due to FB-specific GSK-3α deletion. Further molecular studies confirmed that FB-GSK-3α could regulate NF-kB activation and expression of angiogenesis-related proteins. Our findings suggest that FB-GSK-3α plays a critical role in the pathological cardiac remodeling of ischemic hearts, therefore, it could be therapeutically targeted.</p>","PeriodicalId":8723,"journal":{"name":"Basic Research in Cardiology","volume":"118 1","pages":"35"},"PeriodicalIF":7.5,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11340261/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10151443","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Myeloperoxidase is a critical mediator of anthracycline-induced cardiomyopathy. 髓过氧化物酶是蒽环类药物诱导的心肌病的关键介质。
IF 9.5 1区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2023-09-01 DOI: 10.1007/s00395-023-01006-0
Felix Sebastian Nettersheim, Johannes David Schlüter, Wiebke Kreuzberg, Dennis Mehrkens, Simon Grimm, Harshal Nemade, Simon Braumann, Alexander Hof, Henning Guthoff, Vera Peters, Friedrich Felix Hoyer, Yulia Kargapolova, Jan-Wilm Lackmann, Stefan Müller, Christian P Pallasch, Michael Hallek, Agapios Sachinidis, Matti Adam, Holger Winkels, Stephan Baldus, Simon Geißen, Martin Mollenhauer

Cardiotoxicity is a major complication of anthracycline therapy that negatively impacts prognosis. Effective pharmacotherapies for prevention of anthracycline-induced cardiomyopathy (AICM) are currently lacking. Increased plasma levels of the neutrophil-derived enzyme myeloperoxidase (MPO) predict occurrence of AICM in humans. We hypothesized that MPO release causally contributes to AICM. Mice intravenously injected with the anthracycline doxorubicin (DOX) exhibited higher neutrophil counts and MPO levels in the circulation and cardiac tissue compared to saline (NaCl)-treated controls. Neutrophil-like HL-60 cells exhibited increased MPO release upon exposition to DOX. DOX induced extensive nitrosative stress in cardiac tissue alongside with increased carbonylation of sarcomeric proteins in wildtype but not in Mpo-/- mice. Accordingly, co-treatment of human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) with DOX and MPO aggravated loss of hiPSC-CM-contractility compared to DOX treatment alone. DOX-treated animals exhibited pronounced cardiac apoptosis and inflammation, which was attenuated in MPO-deficient animals. Finally, genetic MPO deficiency and pharmacological MPO inhibition protected mice from the development of AICM. The anticancer efficacy of DOX was unaffected by MPO deficiency. Herein we identify MPO as a critical mediator of AICM. We demonstrate that DOX induces cardiac neutrophil infiltration and release of MPO, which directly impairs cardiac contractility through promoting oxidation of sarcomeric proteins, cardiac inflammation and cardiomyocyte apoptosis. MPO thus emerges as a promising pharmacological target for prevention of AICM.

心脏毒性是蒽环类药物治疗的主要并发症,对预后有负面影响。目前缺乏有效的药物治疗来预防蒽环类药物诱导的心肌病(AICM)。中性粒细胞来源的髓过氧化物酶(MPO)的血浆水平升高可预测人类AICM的发生。我们假设MPO的释放是AICM的原因之一。与生理盐水(NaCl)处理的对照组相比,静脉注射蒽环类药物阿霉素(DOX)的小鼠在循环和心脏组织中表现出更高的中性粒细胞计数和MPO水平。中性粒细胞样HL-60细胞在暴露于DOX后表现出MPO释放增加。DOX在野生型小鼠中诱导了心脏组织中广泛的亚硝化应激,同时增加了肌块蛋白的羰基化,但在Mpo-/-小鼠中没有。因此,与单独DOX治疗相比,用DOX和MPO联合治疗人诱导多能干细胞衍生的心肌细胞(hiPSC CM)加重了hiPSC CM收缩性的丧失。DOX处理的动物表现出明显的心脏细胞凋亡和炎症,这在MPO缺乏的动物中减弱。最后,遗传性MPO缺乏和药理学MPO抑制保护小鼠免受AICM的发展。DOX的抗癌功效不受MPO缺乏的影响。在此,我们将MPO确定为AICM的关键介质。我们证明DOX诱导心脏中性粒细胞浸润和MPO的释放,MPO通过促进肌块蛋白的氧化、心脏炎症和心肌细胞凋亡直接损害心脏收缩性。MPO因此成为预防AICM的一个有前景的药理学靶点。
{"title":"Myeloperoxidase is a critical mediator of anthracycline-induced cardiomyopathy.","authors":"Felix Sebastian Nettersheim, Johannes David Schlüter, Wiebke Kreuzberg, Dennis Mehrkens, Simon Grimm, Harshal Nemade, Simon Braumann, Alexander Hof, Henning Guthoff, Vera Peters, Friedrich Felix Hoyer, Yulia Kargapolova, Jan-Wilm Lackmann, Stefan Müller, Christian P Pallasch, Michael Hallek, Agapios Sachinidis, Matti Adam, Holger Winkels, Stephan Baldus, Simon Geißen, Martin Mollenhauer","doi":"10.1007/s00395-023-01006-0","DOIUrl":"10.1007/s00395-023-01006-0","url":null,"abstract":"<p><p>Cardiotoxicity is a major complication of anthracycline therapy that negatively impacts prognosis. Effective pharmacotherapies for prevention of anthracycline-induced cardiomyopathy (AICM) are currently lacking. Increased plasma levels of the neutrophil-derived enzyme myeloperoxidase (MPO) predict occurrence of AICM in humans. We hypothesized that MPO release causally contributes to AICM. Mice intravenously injected with the anthracycline doxorubicin (DOX) exhibited higher neutrophil counts and MPO levels in the circulation and cardiac tissue compared to saline (NaCl)-treated controls. Neutrophil-like HL-60 cells exhibited increased MPO release upon exposition to DOX. DOX induced extensive nitrosative stress in cardiac tissue alongside with increased carbonylation of sarcomeric proteins in wildtype but not in Mpo<sup>-/-</sup> mice. Accordingly, co-treatment of human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) with DOX and MPO aggravated loss of hiPSC-CM-contractility compared to DOX treatment alone. DOX-treated animals exhibited pronounced cardiac apoptosis and inflammation, which was attenuated in MPO-deficient animals. Finally, genetic MPO deficiency and pharmacological MPO inhibition protected mice from the development of AICM. The anticancer efficacy of DOX was unaffected by MPO deficiency. Herein we identify MPO as a critical mediator of AICM. We demonstrate that DOX induces cardiac neutrophil infiltration and release of MPO, which directly impairs cardiac contractility through promoting oxidation of sarcomeric proteins, cardiac inflammation and cardiomyocyte apoptosis. MPO thus emerges as a promising pharmacological target for prevention of AICM.</p>","PeriodicalId":8723,"journal":{"name":"Basic Research in Cardiology","volume":"118 1","pages":"36"},"PeriodicalIF":9.5,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10474188/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10151445","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Identification of the specific molecular and functional signatures of pre-beta-HDL: relevance to cardiovascular disease. 前- hdl特异性分子和功能特征的鉴定:与心血管疾病的相关性
IF 9.5 1区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2023-08-28 DOI: 10.1007/s00395-023-01004-2
Isabelle Guillas, Marie Lhomme, Cédric Pionneau, Lucrèce Matheron, Maharajah Ponnaiah, Sophie Galier, Sandrine Lebreton, Marie Delbos, Feng Ma, Maryam Darabi, Petra El Khoury, Marianne Abifadel, Philippe Couvert, Philippe Giral, Philippe Lesnik, Maryse Guerin, Wilfried Le Goff, Anatol Kontush

While low concentrations of high-density lipoprotein-cholesterol (HDL-C) are widely accepted as an independent cardiovascular risk factor, HDL-C-rising therapies largely failed, suggesting the importance of both HDL functions and individual subspecies. Indeed HDL particles are highly heterogeneous, with small, dense pre-beta-HDLs being considered highly biologically active but remaining poorly studied, largely reflecting difficulties for their purification. We developed an original experimental approach allowing the isolation of sufficient amounts of human pre-beta-HDLs and revealing the specificity of their proteomic and lipidomic profiles and biological activities. Pre-beta-HDLs were enriched in highly poly-unsaturated species of phosphatidic acid and phosphatidylserine, and in an unexpectedly high number of proteins implicated in the inflammatory response, including serum paraoxonase/arylesterase-1, vitronectin and clusterin, as well as in complement regulation and immunity, including haptoglobin-related protein, complement proteins and those of the immunoglobulin class. Interestingly, amongst proteins associated with lipid metabolism, phospholipid transfer protein, cholesteryl ester transfer protein and lecithin:cholesterol acyltransferase were strongly enriched in, or restricted to, pre-beta-HDL. Furthermore, pre-beta-HDL potently mediated cellular cholesterol efflux and displayed strong anti-inflammatory activities. A correlational network analysis between lipidome, proteome and biological activities highlighted 15 individual lipid and protein components of pre-beta-HDL relevant to cardiovascular disease, which may constitute novel diagnostic targets in a pathological context of altered lipoprotein metabolism.

虽然低浓度的高密度脂蛋白-胆固醇(HDL- c)被广泛认为是一个独立的心血管危险因素,但HDL- c升高的治疗在很大程度上失败了,这表明HDL功能和个体亚种的重要性。事实上,高密度脂蛋白颗粒是高度不均匀的,小而致密的前-高密度脂蛋白被认为具有高度的生物活性,但研究很少,这在很大程度上反映了它们的纯化困难。我们开发了一种原始的实验方法,允许分离足够数量的人β - hdl前,并揭示其蛋白质组学和脂质组学特征和生物活性的特异性。前- hdl富含磷脂酸和磷脂酰丝氨酸的高度多不饱和种类,以及与炎症反应相关的大量蛋白质,包括血清对氧磷酶/芳基酯酶-1、玻璃体连接蛋白和聚簇蛋白,以及补体调节和免疫,包括接触珠蛋白相关蛋白、补体蛋白和免疫球蛋白类蛋白质。有趣的是,在与脂质代谢相关的蛋白质中,磷脂转移蛋白、胆固醇酯转移蛋白和卵磷脂:胆固醇酰基转移酶在前- hdl中被强烈富集或限制。此外,前- hdl可有效介导细胞胆固醇外排,并显示出强大的抗炎活性。脂质组、蛋白质组和生物活性之间的相关网络分析强调了与心血管疾病相关的前β - hdl的15个单独的脂质和蛋白质成分,这些成分可能构成脂蛋白代谢改变病理背景下的新诊断靶点。
{"title":"Identification of the specific molecular and functional signatures of pre-beta-HDL: relevance to cardiovascular disease.","authors":"Isabelle Guillas, Marie Lhomme, Cédric Pionneau, Lucrèce Matheron, Maharajah Ponnaiah, Sophie Galier, Sandrine Lebreton, Marie Delbos, Feng Ma, Maryam Darabi, Petra El Khoury, Marianne Abifadel, Philippe Couvert, Philippe Giral, Philippe Lesnik, Maryse Guerin, Wilfried Le Goff, Anatol Kontush","doi":"10.1007/s00395-023-01004-2","DOIUrl":"10.1007/s00395-023-01004-2","url":null,"abstract":"<p><p>While low concentrations of high-density lipoprotein-cholesterol (HDL-C) are widely accepted as an independent cardiovascular risk factor, HDL-C-rising therapies largely failed, suggesting the importance of both HDL functions and individual subspecies. Indeed HDL particles are highly heterogeneous, with small, dense pre-beta-HDLs being considered highly biologically active but remaining poorly studied, largely reflecting difficulties for their purification. We developed an original experimental approach allowing the isolation of sufficient amounts of human pre-beta-HDLs and revealing the specificity of their proteomic and lipidomic profiles and biological activities. Pre-beta-HDLs were enriched in highly poly-unsaturated species of phosphatidic acid and phosphatidylserine, and in an unexpectedly high number of proteins implicated in the inflammatory response, including serum paraoxonase/arylesterase-1, vitronectin and clusterin, as well as in complement regulation and immunity, including haptoglobin-related protein, complement proteins and those of the immunoglobulin class. Interestingly, amongst proteins associated with lipid metabolism, phospholipid transfer protein, cholesteryl ester transfer protein and lecithin:cholesterol acyltransferase were strongly enriched in, or restricted to, pre-beta-HDL. Furthermore, pre-beta-HDL potently mediated cellular cholesterol efflux and displayed strong anti-inflammatory activities. A correlational network analysis between lipidome, proteome and biological activities highlighted 15 individual lipid and protein components of pre-beta-HDL relevant to cardiovascular disease, which may constitute novel diagnostic targets in a pathological context of altered lipoprotein metabolism.</p>","PeriodicalId":8723,"journal":{"name":"Basic Research in Cardiology","volume":"118 1","pages":"33"},"PeriodicalIF":9.5,"publicationDate":"2023-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10162496","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Preventing mitochondrial reverse electron transport as a strategy for cardioprotection. 防止线粒体反向电子传递作为心脏保护策略。
IF 9.5 1区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2023-08-28 DOI: 10.1007/s00395-023-01002-4
Hiran A Prag, Michael P Murphy, Thomas Krieg

In the context of myocardial infarction, the burst of superoxide generated by reverse electron transport (RET) at complex I in mitochondria is a crucial trigger for damage during ischaemia/reperfusion (I/R) injury. Here we outline the necessary conditions for superoxide production by RET at complex I and how it can occur during reperfusion. In addition, we explore various pathways that are implicated in generating the conditions for RET to occur and suggest potential therapeutic strategies to target RET, aiming to achieve cardioprotection.

在心肌梗死的情况下,线粒体复合体I上逆电子传递(RET)产生的超氧化物爆发是缺血/再灌注(I/R)损伤过程中损伤的关键触发因素。在这里,我们概述了复合体I的RET产生超氧化物的必要条件以及它如何在再灌注过程中发生。此外,我们探索了与RET发生条件产生有关的各种途径,并提出了针对RET的潜在治疗策略,旨在实现心脏保护。
{"title":"Preventing mitochondrial reverse electron transport as a strategy for cardioprotection.","authors":"Hiran A Prag, Michael P Murphy, Thomas Krieg","doi":"10.1007/s00395-023-01002-4","DOIUrl":"10.1007/s00395-023-01002-4","url":null,"abstract":"<p><p>In the context of myocardial infarction, the burst of superoxide generated by reverse electron transport (RET) at complex I in mitochondria is a crucial trigger for damage during ischaemia/reperfusion (I/R) injury. Here we outline the necessary conditions for superoxide production by RET at complex I and how it can occur during reperfusion. In addition, we explore various pathways that are implicated in generating the conditions for RET to occur and suggest potential therapeutic strategies to target RET, aiming to achieve cardioprotection.</p>","PeriodicalId":8723,"journal":{"name":"Basic Research in Cardiology","volume":"118 1","pages":"34"},"PeriodicalIF":9.5,"publicationDate":"2023-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10462584/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10162498","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Perspective: mitochondrial STAT3 in cardioprotection. 观点:线粒体STAT3在心脏保护中的作用。
IF 9.5 1区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2023-08-24 DOI: 10.1007/s00395-023-01003-3
Petra Kleinbongard

Activation of signal transducer and activator of transcription 3 (STAT3) has been identified as a key cardioprotective signal not only in animal studies but also in humans-in animals, STAT3 is causally involved in cardioprotection. In response to late ischemic conditioning, canonical function of STAT3 activation upregulates the expression of cardioprotective and anti-apoptotic proteins. In its non-canonical function, STAT3 is activated during ischemic conditioning and is part of the cardioprotective cytosolic survival activating factor enhancement pathway. Activated STAT3 is imported and localized to the mitochondria. Mitochondrial STAT3 stimulates the activity of mitochondrial electron transport chain complex I, reduces mitochondrial reactive oxygen species production and mitochondrial permeability transition pore opening. Finally, two novel aspects of STAT activation in cardioprotection are discussed: a genetic variance of the STAT encoding region as a potential primordial confounding variable for cardioprotection, and the cardioprotective potential of sodium-glucose cotransporter 2 inhibitors through STAT3 activation.

激活信号换能器和转录激活因子3 (STAT3)已被确定为一个关键的心脏保护信号,不仅在动物研究中,而且在人类研究中-在动物中,STAT3参与心脏保护。STAT3激活的典型功能上调了心肌保护蛋白和抗凋亡蛋白的表达。在其非规范功能中,STAT3在缺血条件下被激活,是心脏保护性细胞质存活激活因子增强途径的一部分。激活的STAT3被导入并定位于线粒体。线粒体STAT3刺激线粒体电子传递链复合体I的活性,减少线粒体活性氧的产生和线粒体通透性过渡开孔。最后,本文讨论了STAT激活在心脏保护中的两个新方面:STAT编码区域的遗传变异作为心脏保护的潜在原始混杂变量,以及钠-葡萄糖共转运蛋白2抑制剂通过STAT3激活的心脏保护潜力。
{"title":"Perspective: mitochondrial STAT3 in cardioprotection.","authors":"Petra Kleinbongard","doi":"10.1007/s00395-023-01003-3","DOIUrl":"10.1007/s00395-023-01003-3","url":null,"abstract":"<p><p>Activation of signal transducer and activator of transcription 3 (STAT3) has been identified as a key cardioprotective signal not only in animal studies but also in humans-in animals, STAT3 is causally involved in cardioprotection. In response to late ischemic conditioning, canonical function of STAT3 activation upregulates the expression of cardioprotective and anti-apoptotic proteins. In its non-canonical function, STAT3 is activated during ischemic conditioning and is part of the cardioprotective cytosolic survival activating factor enhancement pathway. Activated STAT3 is imported and localized to the mitochondria. Mitochondrial STAT3 stimulates the activity of mitochondrial electron transport chain complex I, reduces mitochondrial reactive oxygen species production and mitochondrial permeability transition pore opening. Finally, two novel aspects of STAT activation in cardioprotection are discussed: a genetic variance of the STAT encoding region as a potential primordial confounding variable for cardioprotection, and the cardioprotective potential of sodium-glucose cotransporter 2 inhibitors through STAT3 activation.</p>","PeriodicalId":8723,"journal":{"name":"Basic Research in Cardiology","volume":"118 1","pages":"32"},"PeriodicalIF":9.5,"publicationDate":"2023-08-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10449977/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10532278","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Rivaroxaban attenuates neutrophil maturation in the bone marrow niche. 利伐沙班减弱骨髓生态位中性粒细胞成熟。
IF 9.5 1区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2023-08-14 DOI: 10.1007/s00395-023-01001-5
R Schneckmann, M Döring, S Gerfer, S Gorressen, S Heitmeier, C Helten, A Polzin, C Jung, M Kelm, A C Fender, U Flögel, M Grandoch

Pharmacological inhibition of factor Xa by rivaroxaban has been shown to mediate cardioprotection and is frequently used in patients with, e.g., atrial fibrillation. Rivaroxaban's anti-inflammatory actions are well known, but the underlying mechanisms are still incompletely understood. To date, no study has focused on the effects of rivaroxaban on the bone marrow (BM), despite growing evidence that the BM and its activation are of major importance in the development/progression of cardiovascular disease. Thus, we examined the impact of rivaroxaban on BM composition under homeostatic conditions and in response to a major cardiovascular event. Rivaroxaban treatment of mice for 7 days markedly diminished mature leukocytes in the BM. While apoptosis of BM-derived mature myeloid leukocytes was unaffected, lineage-negative BM cells exhibited a differentiation arrest at the level of granulocyte-monocyte progenitors, specifically affecting neutrophil maturation via downregulation of the transcription factors Spi1 and Csfr1. To assess whether this persists also in situations of increased leukocyte demand, mice were subjected to cardiac ischemia/reperfusion injury (I/R): 7 d pretreatment with rivaroxaban led to reduced cardiac inflammation 72 h after I/R and lowered circulating leukocyte numbers. However, BM myelopoiesis showed a rescue of the leukocyte differentiation arrest, indicating that rivaroxaban's inhibitory effects are restricted to homeostatic conditions and are mainly abolished during emergency hematopoiesis. In translation, ST-elevation MI patients treated with rivaroxaban also exhibited reduced circulating leukocyte numbers. In conclusion, we demonstrate that rivaroxaban attenuates neutrophil maturation in the BM, which may offer a therapeutic option to limit overshooting of the immune response after I/R.

利伐沙班对Xa因子的药理学抑制已被证明可以介导心脏保护,并经常用于心房颤动等患者。利伐沙班的抗炎作用是众所周知的,但其潜在的机制仍然不完全了解。迄今为止,尽管越来越多的证据表明骨髓及其激活在心血管疾病的发生/进展中具有重要意义,但尚未有研究关注利伐沙班对骨髓(BM)的影响。因此,我们研究了利伐沙班在稳态条件下和对主要心血管事件的反应中对脑内膜组成的影响。利伐沙班治疗小鼠7天后,BM中成熟白细胞明显减少。虽然BM来源的成熟髓系白细胞的凋亡不受影响,但谱系阴性BM细胞在粒细胞-单核细胞祖细胞水平上表现出分化停滞,特别是通过下调转录因子Spi1和Csfr1影响中性粒细胞成熟。为了评估这种情况是否在白细胞需求增加的情况下也持续存在,我们对小鼠进行了心脏缺血/再灌注损伤(I/R):用利伐沙班预处理7天,I/R后72小时心脏炎症减轻,循环白细胞数量降低。然而,骨髓生成显示出对白细胞分化停滞的拯救,这表明利伐沙班的抑制作用仅限于稳态条件下,主要在紧急造血时被消除。换句话说,接受利伐沙班治疗的st段抬高心肌梗死患者也表现出循环白细胞数量减少。总之,我们证明利伐沙班可以减弱脑脊髓炎中性粒细胞的成熟,这可能为限制I/R后免疫反应的过调提供了一种治疗选择。
{"title":"Rivaroxaban attenuates neutrophil maturation in the bone marrow niche.","authors":"R Schneckmann, M Döring, S Gerfer, S Gorressen, S Heitmeier, C Helten, A Polzin, C Jung, M Kelm, A C Fender, U Flögel, M Grandoch","doi":"10.1007/s00395-023-01001-5","DOIUrl":"10.1007/s00395-023-01001-5","url":null,"abstract":"<p><p>Pharmacological inhibition of factor Xa by rivaroxaban has been shown to mediate cardioprotection and is frequently used in patients with, e.g., atrial fibrillation. Rivaroxaban's anti-inflammatory actions are well known, but the underlying mechanisms are still incompletely understood. To date, no study has focused on the effects of rivaroxaban on the bone marrow (BM), despite growing evidence that the BM and its activation are of major importance in the development/progression of cardiovascular disease. Thus, we examined the impact of rivaroxaban on BM composition under homeostatic conditions and in response to a major cardiovascular event. Rivaroxaban treatment of mice for 7 days markedly diminished mature leukocytes in the BM. While apoptosis of BM-derived mature myeloid leukocytes was unaffected, lineage-negative BM cells exhibited a differentiation arrest at the level of granulocyte-monocyte progenitors, specifically affecting neutrophil maturation via downregulation of the transcription factors Spi1 and Csfr1. To assess whether this persists also in situations of increased leukocyte demand, mice were subjected to cardiac ischemia/reperfusion injury (I/R): 7 d pretreatment with rivaroxaban led to reduced cardiac inflammation 72 h after I/R and lowered circulating leukocyte numbers. However, BM myelopoiesis showed a rescue of the leukocyte differentiation arrest, indicating that rivaroxaban's inhibitory effects are restricted to homeostatic conditions and are mainly abolished during emergency hematopoiesis. In translation, ST-elevation MI patients treated with rivaroxaban also exhibited reduced circulating leukocyte numbers. In conclusion, we demonstrate that rivaroxaban attenuates neutrophil maturation in the BM, which may offer a therapeutic option to limit overshooting of the immune response after I/R.</p>","PeriodicalId":8723,"journal":{"name":"Basic Research in Cardiology","volume":"118 1","pages":"31"},"PeriodicalIF":9.5,"publicationDate":"2023-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10425524/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10033536","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The heterocellular heart: identities, interactions, and implications for cardiology. 异细胞心脏:特性、相互作用及对心脏病学的影响。
IF 7.5 1区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2023-07-26 DOI: 10.1007/s00395-023-01000-6
Achim Lother, Peter Kohl

The heterocellular nature of the heart has been receiving increasing attention in recent years. In addition to cardiomyocytes as the prototypical cell type of the heart, non-myocytes such as endothelial cells, fibroblasts, or immune cells are coming more into focus. The rise of single-cell sequencing technologies enables  identification of ever more subtle differences and has reignited the question of what defines a cell's identity. Here we provide an overview of the major cardiac cell types, describe their roles in homeostasis, and outline recent findings on non-canonical functions that may be of relevance for cardiology. We highlight modes of biochemical and biophysical interactions between different cardiac cell types and discuss the potential implications of the heterocellular nature of the heart for basic research and therapeutic interventions.

近年来,心脏的异细胞特性日益受到关注。除了作为心脏原型细胞类型的心肌细胞外,内皮细胞、成纤维细胞或免疫细胞等非心肌细胞也越来越受到关注。单细胞测序技术的兴起使人们能够识别更微妙的差异,并再次引发了细胞身份的定义问题。在此,我们概述了主要的心脏细胞类型,描述了它们在体内平衡中的作用,并概述了可能与心脏病学有关的非典型功能的最新发现。我们强调了不同心脏细胞类型之间的生化和生物物理相互作用模式,并讨论了心脏的异细胞特性对基础研究和治疗干预的潜在影响。
{"title":"The heterocellular heart: identities, interactions, and implications for cardiology.","authors":"Achim Lother, Peter Kohl","doi":"10.1007/s00395-023-01000-6","DOIUrl":"10.1007/s00395-023-01000-6","url":null,"abstract":"<p><p>The heterocellular nature of the heart has been receiving increasing attention in recent years. In addition to cardiomyocytes as the prototypical cell type of the heart, non-myocytes such as endothelial cells, fibroblasts, or immune cells are coming more into focus. The rise of single-cell sequencing technologies enables  identification of ever more subtle differences and has reignited the question of what defines a cell's identity. Here we provide an overview of the major cardiac cell types, describe their roles in homeostasis, and outline recent findings on non-canonical functions that may be of relevance for cardiology. We highlight modes of biochemical and biophysical interactions between different cardiac cell types and discuss the potential implications of the heterocellular nature of the heart for basic research and therapeutic interventions.</p>","PeriodicalId":8723,"journal":{"name":"Basic Research in Cardiology","volume":"118 1","pages":"30"},"PeriodicalIF":7.5,"publicationDate":"2023-07-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10371928/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10372369","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Basic Research in Cardiology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1